Opinion | Vinay Prasad Is Out at the FDA—Again
Source: WSJ.com : U.S. News · Bias: Center
Summary
The high-handed rejection of a treatment for Huntington’s disease shows why the biologics chief had to go.
Related Coverage
- Some Thoughts on the Court's Opinion(s) in the Birthright Citizenship Case (Center Right — Reason.com)
- Opinion | The Supreme Court’s Constitutional Restoration (Center — WSJ.com : U.S. News)
- Opinion | A (Mostly) Happy 250th American Birthday (Center — WSJ.com : U.S. News)
- Opinion | Todd Blanche Affirms the President’s Conduct (Center — WSJ.com : U.S. News)
- Opinion | The Socialist Wave Reaches the Heartland (Center — WSJ.com : U.S. News)
- Opinion | Roberts Gets the 14th Amendment Wrong (Center — WSJ.com : U.S. News)
- Opinion | Tocqueville at the World Cup (Center — WSJ.com : U.S. News)
- Justice Thomas calls transgender language a ‘lie’ in concurring opinion (Center — The Hill News)
More Headlines From March 7, 2026
- DOJ admits to coding errors in Epstein files release (Center)
- AOC, Omar and other ‘Squad’ reps among the 53 House Dems that voted against reaffirming Iran as a terror sponsor (Right)
- Mad as a momma wasp': Republican exposes how Trump rage gave staffer the boot (Left)
- Trump administration takes heat as Americans slowly return from Middle East (Center)
- Will Kristi Noem become the new face of Trump’s Donroe Doctrine? (Right)
